InsidersTradesSigma
Track the Vidac Pharma Holding PLC share price and the full insider trade history of the company, a listed equity based in Germany. Shares are quoted on the DE market, under the authority of BaFin. Operating in the Healthcare & Pharma sector, Vidac Pharma Holding PLC has published 117 reports. Market capitalisation: €36.4m. The latest transaction was reported on 31 August 2026 (Sell). Among the most active insiders: Herzberg, Dr. Max. Every trade is free.
117
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
27Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations117 total
20,000 shares@ €0.44ShareXetraISIN GB00BM9XQ619BAFIN:50089006-b6cb319c90fe
11,000 shares@ €0.45ShareXetraISIN GB00BM9XQ619BAFIN:50089006-e215f7fd8738
7,500 shares@ €0.430.0089% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-fca8a1155630
15,000 shares@ €0.430.018% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-a9cb804a594c
12,611.364 shares@ €0.440.015% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-1791de5dd3d3
15,000 shares@ €0.430.018% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-5f8d5a37bb3a
14,000 shares@ €0.410.016% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-a79edd22e089
2,500 shares@ €0.440.0030% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-022cf4e72e9c
2,104.444 shares@ €0.450.0026% mcap0.4% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-327f973baf34
15,000 shares@ €0.460.019% mcap2.9% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-61753711d3dd
4,000 shares@ €0.460.0051% mcap0.8% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-183d28e48fed
23.522 shares@ €0.460.0000% mcap0.0% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-8be701d81aff
9,347.826 shares@ €0.460.012% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-cbc3ab59b8df
15,000 shares@ €0.480.020% mcap3.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-210a820204ff
17,000 shares@ €0.470.022% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-bfb1dabe682e
6,000 shares@ €0.470.0077% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-544094819b04
10,000 shares@ €0.490.013% mcap2.2% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-fbf403ea0e05
5,000 shares@ €0.490.0067% mcap1.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-dd0c4629a8df
10,204.082 shares@ €0.490.014% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-be37533a04cb
20,408.163 shares@ €0.490.027% mcap4.5% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-ecd54d08e7e9
15,000 shares@ €0.470.019% mcap0.1% of flowShareXetraISIN GB00BM9XQ619BAFIN:50089006-16cc8e3ad1b1
20,708.333 shares@ €0.480.027% mcap0.2% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-4e50bb7fdd28
4,000 shares@ €0.480.0053% mcap0.9% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-c1d9cff6d713
13,410.204 shares@ €0.490.018% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-54b0c7fe23ac
14,000 shares@ €0.470.018% mcap0.1% of flowShareTradegateISIN GB00BM9XQ619BAFIN:50089006-0da5c40845e5
25 of 117 declarations
关于 Vidac Pharma Holding PLC
Vidac Pharma Holding PLC 是一家临床阶段的生物制药公司，在德国 Xetra / 法兰克福（DAX/MDAX/SDAX）上市，明确专注于肿瘤学和肿瘤皮肤病学。该公司成立于 2012 年，围绕癌症代谢的科学方法开发一流疗法，旨在解决癌细胞中观察到的异常代谢过程。这种定位使 Vidac 与许多主要依赖重新配方或后期许可的小市值医疗保健公司相比，具有差异化的特点。（[vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) 尽管该公司注册地址位于英国伦敦 Wenlock Road 20-22 号 N1 7GU，但其对欧洲大陆投资者的股票市场可见性主要集中在德国的 Xetra 和 Tradegate。对于法国、比利时和瑞士的投资者而言，这意味着即使其运营足迹是国际性的，股票也实际上是通过德国市场基础设施进行交易的。（[vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) Vidac 的商业模式专注于两个主要治疗领域：肿瘤学和肿瘤皮肤病学。其主要项目 VDA-1102 正在开发用于治疗光化性角化病和皮肤 T 细胞淋巴瘤 (CTCL) 等适应症。该公司还重点介绍了 VDA-1275，这是一种处于临床前开发阶段的下一代候选药物，在实体瘤方面具有更广泛的潜力。换句话说，其投资案例在很大程度上仍由研发管线驱动，多元化程度有限，但具有明确阐述的科学论证。（[vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) 从竞争角度来看，Vidac 在一个竞争激烈的生物技术环境中运营，差异化取决于生物学实力、专利保护和临床转化质量。该公司将其平台围绕瓦尔堡效应和旨在恢复更正常细胞调节的机制进行构建。这赋予了它独特的科技叙事，但也意味着该股票仍然面临临床阶段生物技术的典型风险：试验结果、监管不确定性和融资需求。（[vidacpharma.com](https://vidacpharma.com/en/about-us/about-us?utm_source=openai)) 公司近期更新表明其持续的科学执行力。2026 年，Vidac 宣布将由 PharmaLegacy 进行一项研究，并报告收到美国专利商标局 (USPTO) 授予的一项新专利授权通知，该专利涵盖 VDA-1102 的合成途径。该公司还披露了根据《市场滥用条例》第 19 条进行的管理层交易，这对于监控内幕交易活动和治理透明度的德国市场投资者而言具有重要意义。这些进展表明，该公司仍处于价值创造阶段，其催化剂与专利进展、临床开发和资本市场准入相关。（[vidacpharma.com](https://vidacpharma.com/en/press-releases?utm_source=openai))
